Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Cancer"
DOI: 10.1038/s41416-020-01042-w
Abstract: Background Regorafenib or trifluridine/tipiracil as third-line treatment have limited efficacy in metastatic colorectal cancer (mCRC). Methods This Phase 2 trial evaluated the efficacy and safety of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS… read more here.
Keywords: irinotecan plus; third line; line; treatment ... See more keywords
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx816
Abstract: Abstract Background Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC). We carried out a randomized, open-label, phase III trial to determine whether S-1… read more here.
Keywords: capeox plus; irinotecan plus; treatment; mfolfox6 capeox ... See more keywords
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
Sign Up to like & getrecommendations! Published in 2020 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000891
Abstract: Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer (ESCC) patients who were previously treated with multiple systemic therapies. Between January 2016 and December 2018, records of… read more here.
Keywords: chemotherapy; esophageal squamous; cancer; irinotecan plus ... See more keywords
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Communications"
DOI: 10.1186/s40880-019-0359-7
Abstract: BackgroundThe benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare… read more here.
Keywords: recurrent metastatic; irinotecan plus; prospective randomized; trial ... See more keywords